JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhoads, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhoads, R. E.

J Biol Chem, Vol. 274, Issue 43, 30337-30340, October 22, 1999

MINIREVIEW
Signal Transduction Pathways That Regulate Eukaryotic Protein Synthesis*

Robert E. RhoadsDagger

From the Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, Shreveport, Louisiana 71130-3932

    INTRODUCTION
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

The last several years have witnessed an explosion in the published literature on two topics, the pathways that transduce extracellular signals to their intracellular targets and modification of the core translational apparatus in response to these signals. Most of these pathways result in cell growth and cell division. Synthesis of the entire complement of proteins is necessary to double the cell size, but synthesis of the so-called "growth-regulated" proteins (1) is needed for cell division. This article summarizes recent advances in our understanding of how a single mitogenic stimulus can simultaneously lead to an increase in both global and growth-regulated protein synthesis.

    Mechanism of Protein Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

The three stages of protein synthesis are catalyzed by initiation, elongation, and release factors (Ref. 2; a guide to current and previous nomenclature can be found in Ref. 3). A ternary complex of eIF2·GTP·Met-tRNAi1 binds to the 40 S ribosomal subunit to form the 43 S initiation complex (Fig. 1). The eIF4 factors plus poly(A)-binding protein recognize the 5'-terminal cap or 3'-terminal poly(A) tract of mRNA, unwind mRNA secondary structure, and transfer it to the 43 S initiation complex, resulting in the 48 S initiation complex. Scanning for the first initiation codon in good sequence context requires eIF4A and the presence of eIF1 and eIF1A (4). Then eIF5 stimulates GTP hydrolysis by eIF2, after which the initiation factors are replaced by the 60 S subunit to form the 80 S initiation complex. The released eIF2·GDP is recycled to eIF2·GTP by the GEF eIF2B. The first elongator aminoacyl-tRNA is brought to the A-site by eEF1, followed by a cycle of GTP hydrolysis and exchange analogous to that of eIF2. Translocation is catalyzed by eEF2, again with a GTP hydrolysis cycle.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Eukaryotic protein synthesis and sites of action for initiation and elongation factors. Factors are abbreviated as: 2, eIF2; 2B, eIF2B; A, eIF4A; E, eIF4E; 4F, eIF4F; G, eIF4G, E1, eEF1; E2, eEF2; S6, ribosomal protein S6. Those factors shown in color are targets of the signaling pathways in Fig. 2.


    Signaling Intermediates Involved in Protein Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

RTKs-- The binding of growth factors to the extracellular domain of RTKs causes a conformational change that induces oligomerization and activation of the intracellular protein Tyr kinase domain (Ref. 5; Fig. 2). Substrates for the kinase can be either the RTK itself or a separate RKS. The SH2 domains of several different signaling molecules dock to the resulting Tyr(P)s in a sequence-specific manner, thereby activating separate downstream signaling cascades.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Signaling pathways leading to alterations in the activities or availability of protein synthesis initiation and elongation factors.

GPCR-- These receptors are coupled to heterotrimeric G-proteins (6). Dissociation of the G-protein subunits activates AC, PLC, and other downstream effectors. PLC hydrolyzes PtdIns(4,5)P2 to DAG and Ins(1,4,5)P3.

RKS-- These are docking proteins for downstream effectors of RTKs (7). The best studied RKS are the insulin receptor substrates, which include IRS-1, IRS-2, IRS-3, Gab-1, and p62DOK. Members of the IRS family bind to insulin receptor via an NH2-terminal PH domain and a Tyr(P)-binding domain. The COOH-terminal portions of the proteins contain numerous Tyr phosphorylation sites. IRS-1 alone provides docking sites for PI3-K, SH-PTP2, Grb-2, Fyn, Nck, and Crk.

SH-PTP2-- This phosphatase contains two SH2 domains, and enzyme activity is maximally activated when both are occupied by Tyr(P)-containing peptides (8). SH-PTP2 is activated by docking to EGF receptor, platelet-derived growth factor receptor, c-kit, insulin receptor, IRS-1, IRS-2, and IRS-3 and may serve to attenuate the Tyr(P) signal in these molecules (7).

Ras-- This G-protein is bound to the plasma membrane by COOH-terminal prenylation and myristoylation (9). GEF activity is provided by SOS, which associates constitutively with the SH2- and SH3-containing protein Grb-2. The Grb-2·SOS complex is recruited to the plasma membrane by binding to specific Tyr(P)s in IRS-1, IRS-2, Shc, or SH-PTP2 (7). Another GEF, Ras-GEF, is stimulated by Ca2+/calmodulin (CaM) downstream of GPCR (10). The hydrolysis of GTP by Ras is stimulated by GTPase-activating proteins such as p120GAP and NF1 (9).

MAPKs-- Ras·GTP activates the Ser/Thr kinase Raf-1 by recruiting it to the plasma membrane. Raf-1, in turn, phosphorylates and activates MEK1 and MEK2. The MEKs are dual specificity kinases, phosphorylating both Thr and Tyr residues in ERK1 and ERK2 (p42 and p44 MAPKs).

PI3-K-- This kinase is composed of a catalytic subunit and a SH2-containing regulatory subunit that binds to Tyr(P)s in RTKs and RKS (7). PI3-K is also activated synergistically by direct binding to Ras·GTP (11). PI3-K is a dual specificity kinase that phosphorylates PtdIns at the 3-position and proteins on Ser/Thr residues (12). The lipid phosphorylation signal activates PDK and PKB, and the protein phosphorylation signal activates MAPK (13). Both activities are inhibited by wortmannin and LY294002 (14).

PDKs-- These recently discovered kinases, with at least four isoforms, bind to and are activated by PtdIns(3,4,5)P3 by their COOH-terminal PH domains (15, 16).

PKB (Akt, RAC-PK)-- PKB exists in at least four isoforms (alpha , beta 1, beta 2, gamma ) and is activated by both RTKs and GPCR. In the former case, PI3-K is involved (17), but in the latter, there are both PI3-K-dependent (18) and -independent (19) pathways. PKB is targeted to the plasma membrane by direct binding to PtdIns(3,4)P2 and PtdIns(3,4,5)P3 through its PH domain (20), where it is activated by phosphorylation at Thr-308 by PDK (15).

PKC-- There are at least 10 isoforms of PKC (alpha -zeta ) that differ in responsiveness to phospholipids and Ca2+ (21). Classical PKCs (alpha , beta , and gamma ) are activated and eventually down-regulated by phorbol esters, which are structural analogs of the physiological signal DAG, but atypical isoforms (lambda  and zeta ) are not. Insulin activates both classical and atypical isoforms (22, 23). PKCzeta is activated downstream of PI3-K (24) via direct phosphorylation at Thr-410 by PDK1 (25).

Ca2+-- Changes in cytosolic Ca2+ levels can occur by at least two mechanisms (26). First, GPCR operate Ca2+ channels that allow influx from the extracellular space. Second, Ins(1,4,5)P3, released in response to both RTKs and GPCR, binds to receptors in the endoplasmic reticulum and releases Ca2+ into the cytosol.

GSK-3-- This kinase regulates numerous cellular processes besides phosphorylation of glycogen synthase, including insulin-stimulated protein synthesis (27). Phosphorylation of GSK-3 at Ser-9 inactivates the enzyme and is correlated with the activation of protein synthesis. GSK-3 is phosphorylated directly by PKB in vivo (28, 29).

mTOR (FRAP, RAFT-1)-- mTOR is a 290-kDa protein kinase that is activated by PKB (30) and phosphorylates Ser/Thr-Pro motifs (31). As the name implies, its kinase activity is inhibited by the immunosuppressant rapamycin (31). The ability of insulin to cause phosphorylation and activation of mTOR is attenuated by cAMP (32).

Ribosomal S6 Kinases-- The major activity responsible for phosphorylation of ribosomal protein S6 is p70S6K (33), which is activated by hierarchical phosphorylation of seven Ser/Thr sites. Phosphorylation of COOH-terminal sites occurs first, making Thr-389 available for phosphorylation by a rapamycin-sensitive pathway (34) and culminating in phosphorylation of Thr-229 by constitutively active PDK1 (35). Multipotential S6 kinase is activated and becomes membrane-associated in response to insulin (36). p90S6K is activated in response to growth factors by forming complexes with ERK1 and -2 and undergoing phosphorylation (37). Additional S6 kinases continue to be discovered (38, 39).

PHAS (4E-BP)-- PHAS-I was originally observed as a phosphorylated protein that increased upon insulin treatment of cells but was later found to bind eIF4E specifically (40). Two additional isoforms have since been found, PHAS-II and PHAS-III (41). Phosphorylation of PHAS occurs at six or more sites, two to five of which appear to result from direct phosphorylation by mTOR (34, 42).

Mnk1 and -2-- These kinases, homologous to p90S6K, were identified as binding partners of ERK1 and -2 (43) and in a screen for ERK1 substrates (44). Mnk is activated by phosphorylation at Thr-197 and Thr-202 both by a mitogen-activated pathway via ERK1 or -2 and also by a stress-activated pathway via p38 (45). Interestingly, Mnk1 also binds to the COOH terminus of eIF4G (45, 46).

eEF2K (CaMK III)-- This kinase is activated by Ca2+/CaM and contains a putative CaM-binding domain COOH-terminal to the catalytic domain (47). eEF2 kinase is also activated by cAMP, independently of Ca2+ (48).

    Components of the Core Translational Machinery That Are Targets of Signaling Pathways
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

Two types of signal-induced modifications of translation factors have been described to date: changing the intrinsic activity or binding properties of the factor by phosphorylation and sequestration of the factor in an inactive complex, the formation or dissociation of which may be controlled by phosphorylation.

eIF2-- Most situations that lead to phosphorylation of eIF2alpha represent cellular stress, but eIF2alpha phosphorylation also changes as a result of normal signaling pathways, e.g. those regulated by amino acids (49) and interleukin-3 (50). Phosphorylation of eIF2alpha on Ser-51 by several different kinases causes formation of a stable complex with eIF2B (Fig. 1), thereby reducing the concentration of active eIF2B (51).

eIF2B-- This GEF is phosphorylated on the epsilon  subunit and inactivated by GSK-3alpha and -beta (52). Phosphorylation occurs at Ser-540, although evidence suggests that a priming phosphorylation at Ser-544 by some other kinase is needed (53).

eIF4E-- The mRNA cap-binding protein is phosphorylated at Ser-209 in vivo (54, 55) by Mnk1 and -2 (43, 45), resulting in an increase of its affinity for caps (56). eIF4E variants unable to bind eIF4G are poorly phosphorylated (46). The availability of eIF4E is also regulated by formation of an inactive complex with PHAS, and phosphorylation of PHAS causes dissociation of the complex (57, 58). The relationship between these two eIF4E regulatory mechanisms is unclear. In vitro, PHAS inhibits eIF4E phosphorylation by Mnk1 (59), but in vivo, eIF4E is extensively phosphorylated in cells overexpressing PHAS, suggesting that eIF4E phosphorylation is independent of PHAS (45).

eIF4G-- This linking protein, as part of the eIF4F complex, is phosphorylated at unknown sites by multipotential S6 kinase (60). The phosphorylated complex is more stimulatory for in vitro protein synthesis and binding of mRNA to the 43 S initiation complex.

S6-- This ribosomal protein is phosphorylated at five Ser residues, located at 235, 236, 240, 244, and 247 (33). However, the effect of S6 phosphorylation on protein synthesis is unclear. There is a correlation between activation of p70S6K and translation of mRNAs containing a 5'-TOP tract (61), and treatment of 80 S ribosomes with multipotential S6 kinase increases the rate of elongation 2-fold (36). A recent study implicates S6 phosphorylation in the interaction between 40 S subunits and mRNA (62).

eEF1-- The first of the elongation factors is composed of alpha , beta , gamma , and delta  subunits. Various subunits are phosphorylated in vitro by several kinases, including casein kinase II, multipotential S6 kinase, and PKC (36). In the latter two cases, these phosphorylations result in a stimulation of elongation and GDP/GTP exchange, respectively.

eEF2-- This elongation factor is inhibited by phosphorylation via eEF2 kinase on Thr-56 and Thr-58, the phosphorylation of the latter site requiring prior phosphorylation of the former (26, 63).

    Examples of Specific Signaling Pathways Affecting Protein Synthesis
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

Insulin-- Insulin, by far the best characterized effector of protein synthesis, stimulates both initiation and elongation. eIF2alpha phosphorylation does not change, but eIF2B activity nonetheless increases by the pathway IRS-1 (Tyr-608, -628, and -658; Ref. 64) right-arrow PI3-K (64) right-arrow PDK right-arrow PKB (65) right-arrow GSK-3 (28) right-arrow eIF2Bepsilon (53) (see Fig. 2). However, insulin may activate eIF2B through additional routes, because constitutively active PKCzeta stimulates general protein synthesis in an insulin-dependent manner without activating p70S6K, suggesting that PKB is not involved (23). Binding of SH-PTP2 to IRS-1(Tyr-1172 and -1222) attenuates insulin-stimulated protein synthesis (66). PHAS-I is phosphorylated in response to insulin (58, 57) through a rapamycin-sensitive but MAPK-insensitive pathway (64, 67, 68) that includes PKB (69), indicating that the pathway is IRS-1 (Tyr-608, -628, and -658) right-arrow PI3-K right-arrow PDK right-arrow PKB right-arrow mTOR right-arrow PHAS. Phosphorylation of eIF4E is by the pathway IRS-1 (Tyr-895) right-arrow Grb-2·SOS right-arrow Ras right-arrow Raf right-arrow MEK right-arrow ERK right-arrow Mnk. (There are numerous other RKS that contribute to insulin stimulation of MAPK, especially Shc.) eIF4E association with eIF4G is stimulated by insulin (70) as is eIF4G phosphorylation (60). Insulin also stimulates elongation by two mechanisms: phosphorylation of eEF1 and S6, the latter occurring by both multipotential S6 kinase (36) and p70S6K (71), and dephosphorylation of eEF2 via a rapamycin-sensitive route (72). Other growth factors acting through RTKs produce similar changes, e.g. platelet-derived growth factor, nerve growth factor, and EGF (73, 74).

Amino Acids-- Addition of amino acids to starved mammalian cells causes many of the same modifications as insulin, but some of the pathways appear to be different. The activity of eIF2B is increased, partly through dephosphorylation of eIF2alpha and partly through phosphorylation of eIF2Bepsilon , but GSK-3 activity is not altered (75). Like insulin, amino acids cause phosphorylation of p70S6K and PHAS through a mTOR-dependent pathway (76-79). Unlike insulin, however, the pathway does not involve PKB (78, 77) but does involve tRNA aminoacylation (80). The insulin- or IGF-1-mediated phosphorylation of p70S6K and PHAS-I requires amino acids (76, 79). In the presence of insulin, amino acids activate eIF2B but not eIF4E (75).

GPCR-- Less is known about the regulation of protein synthesis by GPCR per se. Angiotensin causes phosphorylation of eIF4E (81) and PHAS-I (82), the µ-opioid receptor activates p70S6K (83), and gastrin leads to PHAS-I phosphorylation (84). However, much has been published on the effects of phorbol esters, which mimic DAG, on protein synthesis. Phorbol esters cause phosphorylation of eIF2B through GSK-3 (52), eIF4E through Mnk1 (43, 44, 59), eIF4G (85), S6 (85), and eEF1 (86). Although this pattern is reminiscent of insulin, phorbol esters do not operate through PI3-K (23).

Ca2+-- Changes in the level of intracellular Ca2+ and its distribution among compartments affect protein synthesis in at least two ways (26). Depletion of Ca2+ from the sarcoplasmic/endoplasmic reticulum by hormones like vasopressin inhibits initiation by phosphorylation of eIF2alpha via PKR (87). Elevation of cytosolic Ca2+ by agents such as bradykinin inhibits elongation by phosphorylation of eEF2 via eEF2K (26). Similarly, stimulation of the NMDA receptor causes eEF2 phosphorylation (88).

    Modification of Initiation Factors Can Affect the Spectrum of mRNAs Translated
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

Signaling pathways do not stimulate translation of all mRNAs equally. Messenger RNAs differ widely in translational efficiency. Factors contributing to low efficiency of translation include a highly structured 5'-UTR, the presence of upstream AUGs, and poor sequence context for the initiating AUG (89), all of which are found in the 5'-UTRs of mRNAs for scarce proteins (90). mRNAs with these properties encode a disproportionate share of proteins involved in cell growth and cell cycle progression (89). These mRNAs are poorly translated in quiescent cells but preferentially recruited to ribosomes after a mitogenic signal (91-93). Overexpression of eIF4E in cultured cells preferentially stimulates translation of a number of mRNAs with high 5'-UTR secondary structure that are involved in cell growth and division (89). Expression of cell cycle-dependent proteins like c-Myc (64) and cyclin D (94) requires mTOR, and inhibition of mTOR with rapamycin prolongs the G1 phase in both T-cells (95) and yeast (96). These results suggest that pathways which activate the unwinding machinery, i.e. by phosphorylation of eIF4E, eIF4G, or PHAS, disproportionately stimulate translation of growth-regulated mRNAs with high 5'-UTR secondary structure.

5'-TOP mRNAs are also differentially regulated in response to extracellular signals (97). These encode many translational components, including ribosomal proteins, eEF1alpha , eEF2, and poly(A)-binding protein. 5'-TOP mRNAs are recruited to polysomes in a growth-dependent fashion that is selectively inhibited by rapamycin (72, 98). This finding alone does not distinguish between signaling through PHAS and signaling through p70S6K, because the pathway bifurcates downstream of mTOR (99) (see Fig. 2). However, ectopic expression of a dominant interfering p70S6K blocks both activation of p70S6K and 5'-TOP mRNA translation, indicating a direct role for p70S6K (61).

The insulin-stimulated pathways to general protein synthesis and to growth-regulated protein synthesis in 32D cells can be dissected with rapamycin (64). Insulin-stimulated total protein synthesis is inhibited only ~10%, and actin synthesis is not affected at all, but insulin-stimulated c-Myc synthesis is completely inhibited. Also, expression of constitutively active PKCzeta in the absence of IRS-1, which bypasses the mTOR pathway, permits insulin-stimulated general protein synthesis but not c-Myc synthesis (23). This suggests that the insulin signal bifurcates at some point after PI3-K, one pathway stimulating general protein synthesis through eIF2B and one stimulating growth-regulated protein synthesis, accounting for ~10% of the total, through eIF4E and S6. Similarly, T-cell activation causes 13% of the pre-existing mRNAs to be recruited to ribosomes (100), and rapamycin causes a 15% decrease in protein synthesis in activated T-cells (95).

    Conclusions and Future Directions
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

Protein synthesis is one of the most complicated biochemical processes undertaken by the cell, requiring roughly 150 different polypeptides and 70 different RNAs. Yet only seven polypeptides (eIF2alpha , eIF2Bepsilon , eIF4E, eIF4G, S6, eEF1, and eEF2) have been identified as targets for regulatory pathways to date. Early observations that multiple initiation and elongation factors were phosphorylated in response to a single extracellular signal (101, 102) may have suggested unnecessary redundancy. This now seems more comprehensible when it is realized that modification of some factors affects the overall rate of translation whereas modification of others affects the spectrum of mRNAs translated. Understanding the pathways for regulation of protein synthesis holds promise for novel approaches for cancer intervention (e.g. Ref. 103), especially if pathways leading to growth-dependent protein synthesis can be selectively inhibited.

    FOOTNOTES

* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. This work was supported by Grant GM20818 from the National Institute of General Medical Sciences.

Dagger To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Louisiana State University Medical Center, 1501 Kings Highway, Shreveport, LA 71130-3932. Tel.: 318-675-5161; Fax: 318-675-5180; E-mail: rrhoad@lsumc.edu.

    ABBREVIATIONS

The abbreviations used are: eIF, eukaryotic initiation factor; aa, amino acids; AC, adenylate cyclase; CaM, calmodulin; DAG, diacylglycerol; eEF, eukaryotic elongation factor; eEF2K, eEF2 kinase; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; GEF, guanine nucleotide exchange factor; GPCR, G-protein-coupled receptors; GSK-3, glycogen synthase kinase-3; Ins, inositol; IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein/ERK kinase; Mnk, MAPK-interacting kinase; mTOR, mammalian target of rapamycin; p70S6K, 70-kDa ribosomal S6 kinase; p90S6K, 90-kDa ribosomal S6 kinase; PDK, PtdIns-dependent kinase; PH, pleckstrin homology; PHAS, phosphorylated, heat- and acid-stable protein; PI3-K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C; PtdIns, phosphatidylinositol; RKS, receptor kinase substrates; RTK, receptor tyrosine kinase; SH2, Src homology domain 2; SH-PTP2, SH2-containing phosphotyrosine phosphatase-2; TOP, terminal oligopyrimidine; UTR, untranslated region.

    REFERENCES
TOP
INTRODUCTION
Mechanism of Protein Synthesis
Signaling Intermediates...
Components of the Core...
Examples of Specific Signaling...
Modification of Initiation...
Conclusions and Future...
REFERENCES

1. Baserga, R. (1990) Cancer Res. 50, 6769-6771[Free Full Text]
2. Merrick, W. C., and Hershey, J. W. B. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 31-69, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
3. Clark, B. F. C., Grunberg-Manago, M., Gupta, N. K., Hershey, J. W. B., Hinnebusch, A. G., Jackson, R. J., Maitra, U., Mathews, M. B., Merrick, W. C., Rhoads, R. E., Sonenberg, N., Spremulli, L., Trachsel, H., and Voorma, H. O. (1996) Biochimie (Paris) 78, 11-12[CrossRef]
4. Pestova, T. V., Borukhov, S. I., and Hellen, C. U. T. (1998) Nature 394, 854-859[CrossRef][Medline] [Order article via Infotrieve]
5. Marshall, C. J. (1995) Cell 80, 179-185[CrossRef][Medline] [Order article via Infotrieve]
6. Vaughan, M. (1998) J. Biol. Chem. 273, 17297[Free Full Text]
7. White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve]
8. Pluskey, S., Wandless, T. J., Walsh, C. T., and Shoelson, S. E. (1995) J. Biol. Chem. 270, 2897-2900[Abstract/Free Full Text]
9. Vojtek, A. B., and Der, C. J. (1998) J. Biol. Chem. 273, 19925-19928[Free Full Text]
10. Downward, J. (1998) Nature 396, 416-417[CrossRef][Medline] [Order article via Infotrieve]
11. Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., and Downward, J. (1996) EMBO J. 15, 2442-2451[Medline] [Order article via Infotrieve]
12. Divecha, N., and Irvine, R. F. (1995) Cell 80, 269-278[CrossRef][Medline] [Order article via Infotrieve]
13. Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R., and Wymann, M. P. (1998) Science 282, 293-296[Abstract/Free Full Text]
14. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) J. Biol. Chem. 269, 5241-5248[Abstract/Free Full Text]
15. Stokoe, D., Stephens, L., Copeland, T., Gaffney, R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., and Hawkins, P. T. (1997) Science 277, 567-570[Abstract/Free Full Text]
16. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, R. J., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins, P. T. (1998) Science 279, 710-714[Abstract/Free Full Text]
17. Wijkander, J., Holst, L. S., Rahn, T., Resjo, S., Castan, I., Manganiello, V., Belfrage, P., and Degerman, E. (1997) J. Biol. Chem. 272, 21520-21526[Abstract/Free Full Text]
18. Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A., and Gutkind, J. S. (1998) J. Biol. Chem. 273, 19080-19085[Abstract/Free Full Text]
19. Moule, S. K., Welsh, G. I., Edgell, N. J., Foulstone, E. J., Proud, C. G., and Denton, R. M. (1997) J. Biol. Chem. 272, 7713-7719[Abstract/Free Full Text]
20. Sable, C. L., Filippa, N., Filloux, C., Hemmings, B. A., and Obberghen, E. V. (1998) J. Biol. Chem. 273, 29600-29606[Abstract/Free Full Text]
21. Dekker, L. V., and Parker, P. J. (1994) Trends Biochem. Sci. 19, 73-77[CrossRef][Medline] [Order article via Infotrieve]
22. Bandyopadhyay, G., Standaer, M. L., Zhao, L., Yu, B., Avignon, A., Galloway, L., Karnam, P., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 2551-2558[Abstract/Free Full Text]
23. Mendez, R., Kollmorgen, G., White, M. F., and Rhoads, R. E. (1997) Mol. Cell. Biol. 17, 5184-5192[Abstract]
24. Herrera-Velit, P., Knutson, K. L., and Reiner, N. E. (1997) J. Biol. Chem. 272, 16445-16452[Abstract/Free Full Text]
25. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Allessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
26. Nairn, A., and Palfrey, H. C. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 295-318, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
27. Cross, D. A. E., Allessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
28. Hajduch, E., Alessi, D. R., Hemmings, B. A., and Hundal, H. S. (1998) Diabetes 47, 1006-1013[Abstract]
29. van Weeren, P. C., Bruyn, M. T., de Vries-Smits, M. M., van Lint, J., and Burgering, B. M. (1998) J. Biol. Chem. 273, 13150-13156[Abstract/Free Full Text]
30. Scott, P. H., Brunn, G. J., Kohn, R. A., and Lawrence, J. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7772-7777[Abstract/Free Full Text]
31. Abraham, R. T., and Wiederrecht, G. J. (1996) Annu. Rev. Immunol. 14, 483-510[CrossRef][Medline] [Order article via Infotrieve]
32. Scott, P. H., and Lawrence, J. C. (1998) J. Biol. Chem. 273, 34496-34501[Abstract/Free Full Text]
33. Proud, C. G. (1996) Trends Biochem. Sci. 21, 181-185[CrossRef][Medline] [Order article via Infotrieve]
34. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1432-1437[Abstract/Free Full Text]
35. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710[Abstract/Free Full Text]
36. Chang, Y. W., and Traugh, J. A. (1997) J. Biol. Chem. 272, 28252-28257[Abstract/Free Full Text]
37. Smith, J. A., Poteet-Smith, C. E., Malarkey, K., and Sturgill, T. W. (1999) J. Biol. Chem. 274, 2893-2898[Abstract/Free Full Text]
38. Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., and Kozma, S. C. (1998) EMBO J. 17, 6649-6659[CrossRef][Medline] [Order article via Infotrieve]
39. New, L., Zhao, M., Li, Y., Bassett, W. W., Feng, Y., Ludwig, S., Padova, F. D., Gram, H., and Han, J. (1999) J. Biol. Chem. 274, 1026-1032[Abstract/Free Full Text]
40. Lawrence, J. C., and Abraham, R. T. (1997) Trends Biochem. Sci. 22, 345-349[CrossRef][Medline] [Order article via Infotrieve]
41. Poulin, F., Gingras, A. C., Olsen, H., Chevalier, S., and Sonenberg, N. (1998) J. Biol. Chem. 273, 14002-14007[Abstract/Free Full Text]
42. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., and Abraham, R. T. (1997) Science 277, 99-101[Abstract/Free Full Text]
43. Waskiewicz, A. J., Flynn, A., Proud, C. G., and Cooper, J. A. (1997) EMBO J. 16, 1909-1920[CrossRef][Medline] [Order article via Infotrieve]
44. Fukunaga, R., and Hunter, T. (1997) EMBO J. 16, 1921-1933[CrossRef][Medline] [Order article via Infotrieve]
45. Waskiewicz, A. J., Johnson, J. C., Penn, B., Mahalingam, M., Kimball, S. R., and Cooper, J. A. (1999) Mol. Cell. Biol. 19, 1871-1880[Abstract/Free Full Text]
46. Pyronnet, S., Imataka, H., Gingras, A.-C., Fukunaga, R., Hunter, T., and Sonenberg, N. (1999) EMBO J. 18, 270-279[CrossRef][Medline] [Order article via Infotrieve]
47. Redpath, N. T., Price, N. T., and Proud, C. G. (1996) J. Biol. Chem. 271, 17547-17554[Abstract/Free Full Text]
48. Diggle, T. A., Redpath, N. T., Heesom, K. J., and Denton, R. M. (1998) Biochem. J. 336, 525-529
49. Hinnebusch, A. G. (1997) J. Biol. Chem. 272, 21661-21664[Free Full Text]
50. Ito, T., Jagus, R., and May, W. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7455-7459[Abstract/Free Full Text]
51. Clemens, M. J. (1996) in Translational Control (Hershey, J. W. B. , Mathews, M. B. , and Sonenberg, N., eds) , pp. 139-172, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
52. Welsh, G. I., Miyamoto, S., Price, N. T., Safer, B., and Proud, C. G. (1996) J. Biol. Chem. 271, 11410-11413[Abstract/Free Full Text]
53. Welsh, G. I., Loughlin, A. J., Foulstone, E. J., Price, N. T., and Proud, C. G. (1997) Biochem. Soc. Trans. 25 (suppl.), 191
54. Joshi, B., Cai, A.-L., Keiper, B. D., Minich, W. B., Mendez, R., Beach, C. M., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 14597-14603[Abstract/Free Full Text]
55. Flynn, A., and Proud, C. G. (1995) J. Biol. Chem. 270, 21684-21688[Abstract/Free Full Text]
56. Minich, W. B., Balasta, M. L., Goss, D. J., and Rhoads, R. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7668-7672[Abstract/Free Full Text]
57. Lin, T., Kong, X., Haystead, T. A. J., Pause, A., Belsham, G., Sonenberg, N., and Lawrence, J. C. (1994) Science 266, 653-656[Abstract/Free Full Text]
58. Pause, A., Belsham, G. J., Gingras, A., Donze, O., Lin, T., Lawrence, J. C., and Sonenberg, N. (1994) Nature 371, 762-767[CrossRef][Medline] [Order article via Infotrieve]
59. Wang, X., Flynn, A., Waskiewicz, A. J., Webb, B. L. J., Vries, R. G., Baines, I. A., Cooper, J. A., and Proud, C. G. (1998) J. Biol. Chem. 273, 9373-9377[Abstract/Free Full Text]
60. Morley, S. J., Dever, T. E., Etchison, D., and Traugh, J. A. (1991) J. Biol. Chem. 266, 4669-4672[Abstract/Free Full Text]
61. Jefferies, B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. (1997) EMBO J. 16, 3693-3704[CrossRef][Medline] [Order article via Infotrieve]
62. Chiaberge, S., Cassarino, E., and Mangiarotti, G. (1998) J. Biol. Chem. 273, 27070-27075[Abstract/Free Full Text]
63. Redpath, N. T., Price, N. T., Severinov, K. V., and Proud, C. G. (1993) Eur. J. Biochem. 213, 689-699[Medline] [Order article via Infotrieve]
64. Mendez, R., Myers, M. G., White, M. F., and Rhoads, R. E. (1996) Mol. Cell. Biol. 16, 2857-2864[Abstract]
65. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Masuga, M. (1998) Mol. Cell. Biol. 18, 3708-3717[Abstract/Free Full Text]
66. Myers, M. G., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., and White, M. W. (1998) J. Biol. Chem. 273, 26908-26914[Abstract/Free Full Text]
67. Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., and Lawrence, J. C. (1996) J. Biol. Chem. 27, 5033-5039
68. von Manteuffel, S. R., Gingras, A.-C., Ming, X.-F., Sonenberg, N., and Thomas, G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4076-4080[Abstract/Free Full Text]
69. Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., and Hay, N. (1998) Genes Dev. 12, 502-513[Abstract/Free Full Text]
70. Sinaud, S., Balage, M., Bayle, G., Dardevet, D., Vary, T. C., Kimball, S. R., Jefferson, L. S., and Grizard, J. (1999) Am. J. Physiol. 39, E50-E61
71. Myers, M. G., Grammer, T. C., Wang, L., Sun, X. J., Pierce, J. H., Blenis, J., and White, M. F. (1994) J. Biol. Chem. 269, 28783-28789[Abstract/Free Full Text]
72. Redpath, N. T., Foulstone, E. J., and Proud, C. G. (1996) EMBO J. 15, 2291-2297[Medline] [Order article via Infotrieve]
73. Kleijn, M., Welsh, G. I., Scheper, G. C., Voorma, H. O., Proud, C. G., and Thomas, A. A. M. (1998) J. Biol. Chem. 273, 5536-5541[Abstract/Free Full Text]
74. Fraser, C. S., Pain, V., and Morley, S. J. (1999) J. Biol. Chem. 274, 196-204[Abstract/Free Full Text]
75. Kimball, S. R., Horetsky, R. L., and Jefferson, L. S. (1998) J. Biol. Chem. 273, 30945-30953[Abstract/Free Full Text]
76. Xu, G., Kwon, G., Marshall, C. A., Lin, T.-A., Lawrence, J. C., Jr., and McDaniel, M. L. (1998) J. Biol. Chem. 273, 28178-28184[Abstract/Free Full Text]
77. Wang, X., Campbell, L. E., Miller, C. M., and Proud, C. G. (1998) Biochem. J. 334, 261-267
78. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., and Avruch, J. (1998) J. Biol. Chem. 273, 14484-14494[Abstract/Free Full Text]
79. Shigemitsu, K., Tsujishita, Y., Hara, K., Nanahoshi, M., Avruch, J., and Yonezawa, K. (1999) J. Biol. Chem. 274, 1058-1065[Abstract/Free Full Text]
80. Iiboshi, Y., Pabst, P. J., Kawasome, H., Hosoi, H., Abraham, R. T., Houghton, P. J., and Terada, N. (1999) J. Biol. Chem. 274, 1092-1099[Abstract/Free Full Text]
81. Rao, G. N., Griendling, K. K., Frederickson, R. M., Sonenberg, N., and Alexander, R. W. (1994) J. Biol. Chem. 269, 7180-7184[Abstract/Free Full Text]
82. Fleurent, M., Gingras, A.-C., Sonenberg, N., and Meloche, S. (1997) J. Biol. Chem. 272, 4006-4012[Abstract/Free Full Text]
83. Polakiewicz, R. D., Schiefer, S. M., Gingras, A. C., Sonenberg, N., and Comb, M. J. (1998) J. Biol. Chem. 273, 23534-23541[Abstract/Free Full Text]
84. Pyronnet, S., Gingras, A.-C., Bouisson, M., Kowalski-Chauvel, A., Seva, C., Vaysse, N., Sonenberg, N., and Pradayrol, L. (1998) Oncogene 16, 2219-2227[CrossRef][Medline] [Order article via Infotrieve]
85. Morley, S. J., and Traugh, J. A. (1990) J. Biol. Chem. 265, 10611-10616[Abstract/Free Full Text]
86. Venema, R. C., Peters, H. I., and Traugh, J. A. (1991) J. Biol. Chem. 266, 12574-12580[Abstract/Free Full Text]
87. Reilly, B. A., Brostrom, M. A., and Brostrom, C. O. (1998) J. Biol. Chem. 273, 3747-3755[Abstract/Free Full Text]
88. Scheetz, A. J., Nairn, A. C., and Constantine-Paton, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14771-14775
89. De Benedetti, A., and Harris, A. L. (1999) Int. J. Biochem. Cell Biol. 31, 59-72[CrossRef][Medline] [Order article via Infotrieve]
90. Kochetov, A. V., Ischenko, I. V., Vorobiev, D. G., Kel, A. E., Babenko, V. N., Kisselev, L. L., and Kolchanov, N. A. (1998) FEBS Lett. 440, 351-355[CrossRef][Medline] [Order article via Infotrieve]
91. Darveau, A., Pelletier, J., and Sonenberg, N. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 2315-2319[Abstract/Free Full Text]
92. Manzella, J. M., Rychlik, W., Rhoads, R. E., Hershey, J. W. B., and Blackshear, P. J. (1991) J. Biol. Chem. 266, 2383-2389[Abstract/Free Full Text]
93. Nielsen, F. C., Ostergaard, L., Nielsen, J., and Christiansen, J. (1995) Nature 377, 358-362[CrossRef][Medline] [Order article via Infotrieve]
94. Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., and Rosen, N. (1998) J. Biol. Chem. 273, 29864-29872[Abstract/Free Full Text]
95. Terada, N., Takase, K., Pabst, P., Nairn, A. C., and Gelfand, E. W. (1995) J. Immunol. 155, 3418-3426[Abstract]
96. Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., and Hall, M. N. (1996) Mol. Biol. Cell 7, 25-42[Abstract]
97. Hornstein, E., Git, A., Braunstein, I., Avnil, D., and Meyuhas, O. (1999) J. Biol. Chem. 274, 1708-1714[Abstract/Free Full Text]
98. Jefferies, H. B. J., Reinhard, C., Kozma, S. C., and Thomas, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4441-4445[Abstract/Free Full Text]
99. von Manteuffel, S., Dennis, P. B., Pullen, N., Gingras, A., Sonenberg, N., and Thomas, G. (1997) Mol. Cell. Biol. 17, 5426-5436[Abstract]
100. Garcia-Sanz, J. A., Mikulits, W., Livingstone, A., Lefkovits, I., and Mullner, E. W. (1998) FASEB J. 12, 299-306[Abstract/Free Full Text]
101. Duncan, R., and Hershey, J. W. B. (1985) J. Biol. Chem. 260, 5493-5497[Abstract/Free Full Text]
102. Morley, S. J., and Traugh, J. A. (1989) J. Biol. Chem. 264, 2401-2404[Abstract/Free Full Text]
103. Aktas, H., Fluckiger, R., Acosta, J. A., Savage, J. M., Palakurthi, S. S., and Halperin, J. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8280-8285[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. J. Southgate, B. Neill, O. Prelovsek, A. El-Osta, Y. Kamei, S. Miura, O. Ezaki, T. J. McLoughlin, W. Zhang, T. G. Unterman, et al.
FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle
J. Biol. Chem., July 20, 2007; 282(29): 21176 - 21186.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. Dogra, H. Changotra, N. Wedhas, X. Qin, J. E. Wergedal, and A. Kumar
TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine
FASEB J, June 1, 2007; 21(8): 1857 - 1869.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
B. Leger, R. Cartoni, M. Praz, S. Lamon, O. Deriaz, A. Crettenand, C. Gobelet, P. Rohmer, M. Konzelmann, F. Luthi, et al.
Akt signalling through GSK-3{beta}, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy
J. Physiol., November 1, 2006; 576(3): 923 - 933.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Utsuki, Q.-s. Yu, D. Davidson, D. Chen, H. W. Holloway, A. Brossi, K. Sambamurti, D. K. Lahiri, N. H. Greig, and T. Giordano
Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer's Disease Amyloid-beta Peptide
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 855 - 862.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J Malta-Vacas, C Aires, P Costa, A R Conde, S Ramos, A P Martins, C Monteiro, and M Brito
Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types
J. Clin. Pathol., June 1, 2005; 58(6): 621 - 625.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Shi, A. Sharma, H. Wu, A. Lichtenstein, and J. Gera
Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway
J. Biol. Chem., March 25, 2005; 280(12): 10964 - 10973.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. L. Korneeva, E. A. First, C. A. Benoit, and R. E. Rhoads
Interaction between the NH2-terminal Domain of eIF4A and the Central Domain of eIF4G Modulates RNA-stimulated ATPase Activity
J. Biol. Chem., January 21, 2005; 280(3): 1872 - 1881.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. D. Dinkova, B. D. Keiper, N. L. Korneeva, E. J. Aamodt, and R. E. Rhoads
Translation of a Small Subset of Caenorhabditis elegans mRNAs Is Dependent on a Specific Eukaryotic Translation Initiation Factor 4E Isoform
Mol. Cell. Biol., January 1, 2005; 25(1): 100 - 113.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
E. GRUDZIEN, J. STEPINSKI, M. JANKOWSKA-ANYSZKA, R. STOLARSKI, E. DARZYNKIEWICZ, and R. E. RHOADS
Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency
RNA, September 1, 2004; 10(9): 1479 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. J. Halayko, S. Kartha, G. L. Stelmack, J. McConville, J. Tam, B. Camoretti-Mercado, S. M. Forsythe, M. B. Hershenson, and J. Solway
Phophatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation
Am. J. Respir. Cell Mol. Biol., September 1, 2004; 31(3): 266 - 275.
[Abstract] [Full Text] [PDF]


Home page